The history of Hodgkin's disease is one of the most excitingstories in medicine. The disorder accounts for about 1% of allcancers and is curable in 85 to 95% of cases, depending on itsstage — whether it is localized or disseminated. Indeed,the article by Fermé et al.1 in this issue of the Journalreports on 10-year survival estimates of 97% for patients withearly-stage disease.
In 1832, in an article entitled "On Some Morbid Appearancesof the Absorbent Glands and Spleen,"2 Thomas Hodgkin discussedsix patients with symptoms that differed from those associatedwith inflammation, tuberculosis, and . . . [Full Text of this Article]
Markova, J., Kobe, C., Skopalova, M., Klaskova, K., Dedeckova, K., Plutschow, A., Eich, H. T., Dietlein, M., Engert, A., Kozak, T.
(2009). FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value. Ann Oncol
20: 1270-1274
[Abstract][Full Text]
Bosetti, C., Levi, F., Ferlay, J., Lucchini, F., Negri, E., La Vecchia, C.
(2009). The recent decline in mortality from Hodgkin lymphomas in central and eastern Europe. Ann Oncol
20: 767-774
[Abstract][Full Text]
Olweny, C. L.M., Ziegler, J. L., Papac, R. J., Subbiah, V., Ferme, C., Eghbali, H., Henry-Amar, M.
(2008). Chemotherapy plus Involved-Field Radiation in Early-Stage Hodgkin's Disease. NEJM
358: 742-743
[Full Text]